Dopamine D2 receptor SPECT imaging: Basic in vivo characteristics and clinical applications of123I-IBZM in humans

Hiroshi Toyama, Masanori Ichise, James R. Ballinger, Luis Fornazzari, Joel C. Kirsh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The purposes of this study are to evaluate the utility of kit formulation, the basic in vivo characteristics, and clinical usefulness of dopamine D2 receptor imaging with123I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrodinyl)methyl]-benzamide (123I-IBZM). We studied 22 normal controls, 3 early symptomatic Huntington's disease patients, and 1 patient with visual hallucination on and off neuroleptics.123I-IBZM could be conveniently prepared with a high degree of purity from a kit, but with relatively low radiochemical yield. We demonstrated123I-IBZM receptor binding equilibrium by performing serial SPECT scanning in a normal volunteer. The basal ganglia/frontal cortex (BG/FC) ratios plateaued after the specific binding reached equilibrium approximately 60 minutes after injection. The BG/FC ratio declined significantly with age. The ratios for the Huntington's disease patients were significantly lower than those for normal controls. The images of the patient off neuroleptic therapy showed dramatically increased BG activity compared with those obtained while on therapy. The BG/FC ratio provides an estimate of Bmax/Kd and hence the receptor density. It appears important to perform SPECT early in the equilibrium phase and at a fixed time after injection to obtain significantly high signal to noise ratios.123I-IBZM is an ideal tracer for SPECT including a rotating gamma camera type which can provide estimates of the receptor density objectively by calculating the BG/FC ratio, and is a promising agent for the investigation of dopamine D2 receptors in clinical conditions.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalAnnals of Nuclear Medicine
Volume7
Issue number1
DOIs
Publication statusPublished - 01-03-1993

Fingerprint

Dopamine D2 Receptors
Frontal Lobe
Basal Ganglia
Single-Photon Emission-Computed Tomography
Huntington Disease
Injections
Gamma Cameras
Hallucinations
Antipsychotic Agents
Noise
Healthy Volunteers
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Toyama, Hiroshi ; Ichise, Masanori ; Ballinger, James R. ; Fornazzari, Luis ; Kirsh, Joel C. / Dopamine D2 receptor SPECT imaging : Basic in vivo characteristics and clinical applications of123I-IBZM in humans. In: Annals of Nuclear Medicine. 1993 ; Vol. 7, No. 1. pp. 29-38.
@article{5e074349de704323ae9cde6d4e77763d,
title = "Dopamine D2 receptor SPECT imaging: Basic in vivo characteristics and clinical applications of123I-IBZM in humans",
abstract = "The purposes of this study are to evaluate the utility of kit formulation, the basic in vivo characteristics, and clinical usefulness of dopamine D2 receptor imaging with123I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrodinyl)methyl]-benzamide (123I-IBZM). We studied 22 normal controls, 3 early symptomatic Huntington's disease patients, and 1 patient with visual hallucination on and off neuroleptics.123I-IBZM could be conveniently prepared with a high degree of purity from a kit, but with relatively low radiochemical yield. We demonstrated123I-IBZM receptor binding equilibrium by performing serial SPECT scanning in a normal volunteer. The basal ganglia/frontal cortex (BG/FC) ratios plateaued after the specific binding reached equilibrium approximately 60 minutes after injection. The BG/FC ratio declined significantly with age. The ratios for the Huntington's disease patients were significantly lower than those for normal controls. The images of the patient off neuroleptic therapy showed dramatically increased BG activity compared with those obtained while on therapy. The BG/FC ratio provides an estimate of Bmax/Kd and hence the receptor density. It appears important to perform SPECT early in the equilibrium phase and at a fixed time after injection to obtain significantly high signal to noise ratios.123I-IBZM is an ideal tracer for SPECT including a rotating gamma camera type which can provide estimates of the receptor density objectively by calculating the BG/FC ratio, and is a promising agent for the investigation of dopamine D2 receptors in clinical conditions.",
author = "Hiroshi Toyama and Masanori Ichise and Ballinger, {James R.} and Luis Fornazzari and Kirsh, {Joel C.}",
year = "1993",
month = "3",
day = "1",
doi = "10.1007/BF03164789",
language = "English",
volume = "7",
pages = "29--38",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "1",

}

Dopamine D2 receptor SPECT imaging : Basic in vivo characteristics and clinical applications of123I-IBZM in humans. / Toyama, Hiroshi; Ichise, Masanori; Ballinger, James R.; Fornazzari, Luis; Kirsh, Joel C.

In: Annals of Nuclear Medicine, Vol. 7, No. 1, 01.03.1993, p. 29-38.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dopamine D2 receptor SPECT imaging

T2 - Basic in vivo characteristics and clinical applications of123I-IBZM in humans

AU - Toyama, Hiroshi

AU - Ichise, Masanori

AU - Ballinger, James R.

AU - Fornazzari, Luis

AU - Kirsh, Joel C.

PY - 1993/3/1

Y1 - 1993/3/1

N2 - The purposes of this study are to evaluate the utility of kit formulation, the basic in vivo characteristics, and clinical usefulness of dopamine D2 receptor imaging with123I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrodinyl)methyl]-benzamide (123I-IBZM). We studied 22 normal controls, 3 early symptomatic Huntington's disease patients, and 1 patient with visual hallucination on and off neuroleptics.123I-IBZM could be conveniently prepared with a high degree of purity from a kit, but with relatively low radiochemical yield. We demonstrated123I-IBZM receptor binding equilibrium by performing serial SPECT scanning in a normal volunteer. The basal ganglia/frontal cortex (BG/FC) ratios plateaued after the specific binding reached equilibrium approximately 60 minutes after injection. The BG/FC ratio declined significantly with age. The ratios for the Huntington's disease patients were significantly lower than those for normal controls. The images of the patient off neuroleptic therapy showed dramatically increased BG activity compared with those obtained while on therapy. The BG/FC ratio provides an estimate of Bmax/Kd and hence the receptor density. It appears important to perform SPECT early in the equilibrium phase and at a fixed time after injection to obtain significantly high signal to noise ratios.123I-IBZM is an ideal tracer for SPECT including a rotating gamma camera type which can provide estimates of the receptor density objectively by calculating the BG/FC ratio, and is a promising agent for the investigation of dopamine D2 receptors in clinical conditions.

AB - The purposes of this study are to evaluate the utility of kit formulation, the basic in vivo characteristics, and clinical usefulness of dopamine D2 receptor imaging with123I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrodinyl)methyl]-benzamide (123I-IBZM). We studied 22 normal controls, 3 early symptomatic Huntington's disease patients, and 1 patient with visual hallucination on and off neuroleptics.123I-IBZM could be conveniently prepared with a high degree of purity from a kit, but with relatively low radiochemical yield. We demonstrated123I-IBZM receptor binding equilibrium by performing serial SPECT scanning in a normal volunteer. The basal ganglia/frontal cortex (BG/FC) ratios plateaued after the specific binding reached equilibrium approximately 60 minutes after injection. The BG/FC ratio declined significantly with age. The ratios for the Huntington's disease patients were significantly lower than those for normal controls. The images of the patient off neuroleptic therapy showed dramatically increased BG activity compared with those obtained while on therapy. The BG/FC ratio provides an estimate of Bmax/Kd and hence the receptor density. It appears important to perform SPECT early in the equilibrium phase and at a fixed time after injection to obtain significantly high signal to noise ratios.123I-IBZM is an ideal tracer for SPECT including a rotating gamma camera type which can provide estimates of the receptor density objectively by calculating the BG/FC ratio, and is a promising agent for the investigation of dopamine D2 receptors in clinical conditions.

UR - http://www.scopus.com/inward/record.url?scp=0027339894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027339894&partnerID=8YFLogxK

U2 - 10.1007/BF03164789

DO - 10.1007/BF03164789

M3 - Article

C2 - 8461237

AN - SCOPUS:0027339894

VL - 7

SP - 29

EP - 38

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 1

ER -